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Abstract Coronavirus disease (COVID 19) has involved millions of people all over the world. Tuberculosis 
(TB) continues to affect millions of people every year with high mortality. There is limited literature on the 
occurrence of COVID 19 in patients with TB. We reviewed the available data on various clinical details, 
management, and outcome among patients with COVID-19 and TB. 8 studies reported a total of 80 patients 
with this coinfection. These patients were reported from 9 different countries, with Italy reporting the largest 
number of cases. Migrant, males constituted a major proportion of cases. Most reported patients were symp-
tomatic. Fever, dry cough, and dyspnea were the most commonly reported symptoms. Bilateral ground glass 
opacities were more common in COVID 19 infection and cavitary lesions were more common in patients 
with TB. Most reported TB patients had been found to have mycobacterium tuberculosis from sputum culture 
in the background of pulmonary TB. Most patients of TB were treated with multidrug regimen antitubercular 
therapy. In all 8 studies, COVID 19 was treated as per the local protocol. Mortality was reported in more 
than 10% of patients. Mortality was higher in elderly patients (> 70 years) and amongst patient with multiple 
medical comorbidities. (www.actabiomedica.it)
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R e v i e w s / f o c u s  o n 
Introduction
Following the declaration of the novel coronavirus 
outbreak as a public health emergency by the World 
Health Organization, the Coronavirus disease 2019 
(COVID-19) pandemic continues to be a significant 
global health crisis. (1) As of September 30th, more 
than 33 million people have been affected in 188 coun-
tries.  Reported death has been more than a million. 
Among symptomatic patient’s respiratory manifesta-
tions continues to be predominant.(2) Patients with 
older age, multiple comorbidities including advanced 
chronic obstructive lung disease, and associated car-
diovascular illnesses are reported to be at risk of the 
worst outcome.(3,4) At the same time Tuberculosis 
(TB) continues to a global burden with around 2.5 
million new patients and .3 million  deaths annually.
(5) There is a paucity in clinical literature reporting 
interactions and the impact of TB among patients with 
COVID 19. (6) We did a systemic review to obtain the 
available literature on the clinical manifestation, diag-
nosis, management and outcome among patients with 
coinfection of COVID-19 and TB. 
Methods
We searched in various electronic databases includ-
ing Pub Med, Embase, Medline, and Google scholar 
for articles on COVID-19 and TB. We used keywords 
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including “COVID-19”, “Coronavirus disease 2019” 
“pulmonary tuberculosis”,” TB”, and “tuberculosis”. 
Studies reporting clinical details of COVID-19 and 
TB patients were included in this review.  Publications 
including clinical trials, cohort studies, case-controlled 
studies, case series, and case reports that were published 
between 1 December 2019 to 30 September 2020 were 
eligible to be included in this review. (7) We excluded 
articles that included opinions, letters, recommen-
dations, guidelines, and failed to provide any patient 
related information.  We included peer reviewed arti-
cles on adults with TB and COVID-19, that have been 
published in scientific journals. (8) We also excluded 
abstracts, and preprints that had not undergone peer 
review and published articles on children with the 
coinfection. In this review, we only included articles 
that were published in English. (9)
Results 
As of September 30th, we identified 113 articles 
in PubMed which discussed the details of COVID -19 
and tuberculosis. Among these only 8 articles had 
clinical details of patients with TB and COVID 19 as 
shown in Table 1. One of them was a case series of 
3 patients, four were case reports, and 3 were retro-
spective cohort studies. (10-13). 
Definitions
COVID - 19: Across the studies presence of 
COVID -19 was reported following confirmation with 
molecular biology. In absence of SARS CoV -2 PCR, 
classical bilateral ground glass pattern in HRCT, in a 
patient with a significant risk of exposure was also used 
for diagnosis. (13-16) The diagnosis and management 
of COVID- 19 has been changing constantly. In the 
beginning in view of limited availability of PCR and 
the delayed turnaround time of the result, patients were 
empirically considered COVID – 19 positives based on 
risk of exposure, contact history. Classical imaging find-
ings would often be available before the availability of 
the PCR result. (15) All patients were ultimately found 
to have serological conformation of COVID – 19. 
Number Study Patients Age (Mean) CT finding Mortality
Active Pulmonary TB
1 He et al 1 76 B/L GGO, RUL Cavity -
2 Tadolini et al 42 45.5 B/L GGO, B/L Cavity, U/L cavity +
3 Motta et al 20 70 B/L GGO,
U/L infiltrates
+
4 Kumar et al 1 38 CXR: B/L infiltrates +
5 Tham et al 4 32 CXR: B/L Cavitary lung lesion, B/L 
and U/L pleural effusion
-
6 Farqihi et al 1 60 B/L GGO -
7 Vilbrun et al* 1 26 CXR: Non specific -
Post TB sequalae
1 He et al 2 46.5 B/L GGO -
2 Tadolini et al 7 69 B/L GGO, U/L infiltrates +
Extra Pulmonary TB
1 Ata et al (TB 
meningitis)
1 28 CXR: B/L infiltrates
CT: B/L GGO
-
*Multi Drug Resistant Tuberculosis; B/L: bilateral, GGO: Ground glass opacity, RUL: right upper lobe, U/L: Unilateral, CXR: 
Chest Xray, CT: Computed tomography, TB: Tuberculosis
Table 1. showing the details of reported COVID 19 patients with TB
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TB: Patients were divided into two subgroups. 
Patients with the presence of positive microbiological 
studies were reported to have active disease. Patients 
with a history of TB, and completion of treatment 
were considered to have post TB sequel. Further 
clinical type of TB was classifi ed as Pulmonary and 
extrapulmonary based on the presence of involvement 
of lung parenchyma. Treatment wise TB was reported 
to be pan-susceptible and drug resistant based on the 
available susceptibility profi le of the organism. Mutli-
drug resistant (MDR) TB was defi ned as the presence 
of resistance of the isolate to isoniazid and rifampin. 
(10,11)
COVID -19 and TB coinfection: Th is was defi ned 
with the presence of COVID -19 positivity in patients 
with TB. Patients were further sub grouped based on 
the disease status of TB. Patients with i) newly diag-
nosed TB before the diagnosis of COVID -19, ii) newly 
diagnosed TB after the diagnosis of COVID -19, iii) 
diagnosis of COVID -19 in TB patients who are in the 
middle of completing their treatment were grouped as 
COVID – 19 with active TB. Patients who had any 
history of TB with or without treatment, suspected 
to have latent TB, and had completed antitubercular 
therapy recently were grouped as COVID -19 with 
TB sequel. All studies reporting TB and COVID -19, 
included patients with a diagnosis of TB any time in 
the past to include patients with consequences of TB. 
(10,11,15,17)
Epidemiology
Th ese 8 studies cumulatively reported 80 patients 
with COVID -19 in the background of TB. Seventy 
patients were reported to have active pulmonary tuber-
culosis at the time of COVID – 19 diagnosis. Most 
of these reported cases had been recruited from nine 
countries and three continents, mostly by the Global 
Tuberculosis Network. (10,11,18) Figure 1 shows the 
diff erent countries with reported TB and COVID- 19 
coinfection. To date, Countries reporting TB and 
COVID cases have been Belgium, Brazil, France, 
Italy, Russia, Singapore, Spain, Switzerland, India and 
China. Among these Italy has reported the highest 
percentage of cases (51%). With the recent upsurge of 
cases in developing countries, we can anticipate a rise 
in the numbers of patients with TB and COVID -19 
coinfection. TB and COVID coinfection has been 
reported across both genders and diff erent age groups. 
COVID 19 co-infection has been reported in TB 
patients before diagnosis, after diagnosis, and during 
Figure 1. Showing countries reporting cases of COVID 19 and TB coinfection.
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the entire course of being on treatment for TB. The 
2 cohort studies reported that coinfections were com-
moner in migrants and males. 
Migrants constituted more than 50% of patients 
in both groups. Similarly, both groups had more than 
80% of males. Interestingly one study also reported 
that 41% of the patients were smokers, 31% of the 
patients were unemployed and 20% of the patients 
had a history of alcohol abuse. (11,16)    Both TB and 
COVID-19 are reported to have high infectivity.(19) 
A single COVID-19 patient is known to infect 2.5 
people within a short span of 5 days, and a patient with 
pulmonary tuberculosis can infect around 15 patients 
an year. (20) 
Clinical Features
Pulmonary TB patients present with fever, produc-
tive cough, and constitutional symptoms. In the subsets 
of patients with COVID -19, and TB symptoms at the 
time of presentation continues to be similar to patients 
without TB. (10,11) Unlike patients with isolated 
COVID- 19 illnesses most reported patients with coin-
fection are symptomatic. This could be because of the 
selection bias in recruiting only symptomatic patients 
presenting to the hospital. Fever, dry cough, and dysp-
nea have been reported as the commonest symptoms. 
(11,19) Other reported symptoms have been chest 
tightness, chest pain, and diarrhea. (10) Among symp-
tomatic patients, hypoxia has also been documented 
requiring oxygen supplementation. These studies are 
limited regarding the physical examination findings. 
(10,11) The same could be because of the rapid avail-
ability of microbiological confirmatory testing, imaging 
modalities, and the various other factors contributing to 
a reduction in patient and provider interaction. Among 
patients with TB, COVID-19 can occur before, during 
or after the onset of the illness, which further hinders 
the clinical picture among patients.
Microbiology
Almost all reported patients had mycobacterial 
infections secondary to mycobacterium tuberculosis. 
Sputum culture (45%), Nucleic Acid Amplification 
Test (NAAT-26.5%), and sputum smear positivity 
(18.4%) were used as the diagnostic tool for Tubercu-
losis. There is also a report of infections secondary to 
mycobacterium bovis. Both drug susceptible and drug-
resistant mycobacterial strains have been reported with 
the former being the commoner (82%). Resistance to 
an isolated ATT has been reported in around 18% of 
patients and MDR TB isolates have been identified in 
9% of co infections. (10,11,18)
Laboratory Panel
Initial case series reported the presence of leu-
copenia, lymphocytopenia with elevated inflamma-
tory markers including ESR, CRP and LDH. Other 
reported laboratory abnormalities in this subset of 
patients were low serum albumin, raised ALT, an 
abnormal glucose level, and raised CPK.10 Studies on 
COVID -19 patients have persistently reported mul-
tiple laboratory abnormalities in patients with severe 
disease. Among patients with severe COVID -19 pre-
senting with cytokine storm raised levels of procalci-
tonin, ferritin, interleukin -2 (IL-2), IL-7, and tumor 
necrosis factor have been reported. (21) Similarly, 
severe COVID-19 patients with cardiac injury have 
been reported to have raised levels of troponin, CK –
MB, myoglobin, D – dimer, high sensitive troponin, 
and NT pro BNP. (22) The impact of COVID -19 and 
TB coinfection on inflammatory markers and markers 
of cardiac injury remains unknown.
Imaging
High resolution computed tomography (HRCT) 
and chest radiograph (CXR) has been used to iden-
tify the patterns of pulmonary involvement. (3) Imag-
ing details are available in all (98%) of patients in the 
above studies. (6) HRCT has been the initial modal-
ity of imaging in more than 40% of patients. Imaging 
findings that have been reported in the TB patients 
developing COVID 19 are the development of multi-
ple, bilateral ground glass opacity, and consolidations 
with air bronchogram. (6,11,18) Among patients with 
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TB and COVID 19 unilateral pulmonary infiltrates 
were seen in 33% of patients and bilateral infiltrates 
were reported in 19% of patients. Chest CT findings 
suggesting the diagnosis of pulmonary TB have been 
cavitating lung lesions. (11,18) Among patients with 
TB bilateral cavitary lesions have been reported more 
often (27%) as compared to the unilateral cavitary 
lesion (21%).  Other patterns that have been reported 
in imaging are miliary pattern, crazy paving, and tree 
in bud pattern. The pattern of pulmonary involvement 
secondary to COVID 19 in TB patients continues to 
be the same as that of non-TB patients. (3,6) In this 
subset of patients, GGO is still the commonest pattern 
of pulmonary involvement. Interestingly alike non TB 
patient GGO has been reported to resolve following 
improvement of COVID 19 illness in TB patients as 
well. (14-16) 
Risk Factors: 
Reported predisposing factors in TB patients 
with COVID 19 have been similar to that of TB 
patients without COVID 19. Medical comorbidities 
like COPD, diabetes, HIV, renal failure, liver disease, 
alcohol abuse, and smoking have been reported in the 
study by Tadolini et al. (18) This study also reported 
demographic factors including male gender and 
migrant population in higher proportions of patients. 
As both COVID-19 and TB tend to spread in over-
crowded areas, among poor and malnourished popula-
tion these comorbidities and circumstances can have 
synergistic impact. (15,23)
Types of TB
Both pulmonary (73%) and extra-pulmonary TB 
have been reported among patients with COVID -19, 
with the former being the commoner.  Disseminated 
TB as defined by the presence of evidence of TB in 
multiple (>1) organs have also been reported to have 
COVID-19. Sites of isolated extrapulmonary TB that 
have been reported in COVID -19 patients are lymph 
node, bone, larynx, CNS, gastrointestinal, peritoneal, 
genitourinary, pleural and spinal in location. (18,24) 
Treatment
All the patients with active TB were reported to 
be treated with the multidrug regimen antitubercular 
therapy.  Among patients with pan-susceptible organ-
ism treatment regimen constituted isoniazid, rifampin, 
pyrazinamide, and ethambutol. (3,11) In one patient 
with multidrug resistant TB as detected by resistance to 
rifampicin in Xpert PCR, bedaquiline, levofloxacin, lin-
ezolid, and clofazimine was used in combination with 
pyrazinamide. Various therapeutic agents that were used 
to treat COVID-19 in patients with TB co-infection were 
hydroxychloroquine, azithromycin, lopinavir/ritonavir, 
darunavir/cobicistat combination. (11,18) Glucocorti-
coids including methylprednisolone and dexamethasone 
have also been administered to these subsets of patients. 
There have been reports of administration of anticoagu-
lation (enoxaparin, parnaparine) as well. (18) While the 
antitubercular regimens used were similar, therapies used 
for COVID-19 were varied across all patients.  Most 
treatment details including the reason for the choice of 
therapy, the doses of medications, the duration of medi-
cations, the details of medication interactions, dosage 
modifications and adverse drug events were not reported 
for either form of therapy  consistently. (24,25) 
Complications
Complications that have been reported in this 
subset of patients are hypoxemia, respiratory failure, 
acute respiratory distress syndrome (ARDS), the 
requirement of noninvasive ventilation, glucose abnor-
malities, a prolonged hospital stay (maximum 130 days 
in hospital), and superimposed bacterial infection. 
(3,11,18) Details of other organ involvement were 
mostly not available even in the patients with compli-
cations and mortality. (26,27) 
Mortality
Motta et al described 2 cohorts of patients with TB 
and COVID 19. The first cohort had 49 patients from 
8 countries and the second cohort had 20 hospitalized 
patients with TB and COVID-19. 53% and 85% of 
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patients from these cohorts were migrants. They reported 
a mortality rate of 11.3% and 14.3% in the patients 
respectively. (11) They reported that mortality was more 
likely among elderly patients with COVID 19 and TB. 
The 2 reported contributors to mortality were an age of 
> 70 years and the presence of > 2 medical comorbidi-
ties. Motta et al found that migrants had lesser mortality, 
and they attributed the same to the younger age and the 
absence of medical comorbidities in these patients. (11,18) 
In all three studies, TB was not a major contributor to 
mortality. Among the TB patients with reported mortal-
ity, COVID 19 was contributory to worst outcome and 
mortality. (3,11,18) Interestingly patients with mortality 
had acquired COVID-19 via nosocomial  transmission.
BCG and COVID 19: 
Innate immunity is thought to be instrumental in 
the course and severity of COVID 19. This had been 
postulated based on higher prevalence and mortality 
of COVID -19 patients in countries with a lower rate 
of Bacillus Calmette –Guerin (BCG) administration. 
A recent review showed a strong correlation between 
the BCG and cross protection from COVID -19, with 
every 10% increase in BCG administration resulting 
in 10.4% reduction in COVID – 19 mortality. (28-30)
However, this epidemiological study was not 
designed to show causality and direct association. 
Another study reported that COVID -19 mortality was 
remarkably higher in countries without mandatory BCG 
vaccination. This study reported that seven countries with 
mandatory BCG vaccination for their population had 
lesser mortality as compared to countries that had stopped 
BCG administration for twenty years. This protection 
was reported across different strains of BCG excluding 
Denmark strain. (29,30) In the present scenario, with a 
further increase in the number of cases and mortalities in 
countries with good BCG administration status this con-
cept continues to be clarified further.  Interestingly one of 
the above studies reported that 3 of the 8 patients with 
mortality had been vaccinated with BCG.30
Limitations: 
All the eight articles including the 3 studies have 
been retrospective. These studies lacked a strict inclusion 
and exclusion criteria and have been liberal in defining 
TB.  Given a small sample size, these studies have not 
been able to establish the statistical significance of the 
co-infection. (31) these studies were limited in defin-
ing the severity and patterns of organ involvements in 
patients with COVID-19. Similarly, they were limited 
in terms of laboratory investigations including biochem-
ical profile, inflammatory markers, and coagulation pro-
file. (32,33) They were limited in identifying the impact 
of COVID – 19 on TB and vice versa. These studies did 
not look at the interactions of various drugs that are used 
for treating this subset of patients. (34) We also excluded 
non-English articles and children in this review. 
Future Strategies: 
In future clinical studies should incorporate the 
appropriate classifications of patients with TB and 
COVID 19. Studies should differentiate the various 
factors pertinent to TB, and COVID- 19. (35,36) They 
should incorporate in detail the various parameters 
including clinical presentation, physical findings, and 
detailed laboratory parameters. Consistent reporting 
of clinical outcomes including morbidity, major organ 
involvement, the requirement of intensive care, and 
invasive, noninvasive ventilation, the requirement of 
vasopressors would facilitate further understanding of 
these diseases. (35,37) Future studies should incorporate 
a standardized treatment algorithm for both infections. 
Interactions amongst multiple medications and adverse 
drug events need to be reported. The standardized mul-
tidrug antitubercular regimen can be safely continued 
following physician’s recommendations based on the 
susceptibility pattern. Regimens used for COVID-19 
should be used as per available evidence and guide-
lines in the symptomatic patients. (38) Implementing 
strict infection control interventions for all hospitalized 
patients (particularly for those at higher risk, e.g. elderly 
and patients with co-morbidities including TB) is the 
need of the hour. (39) Among non-hospitalized TB 
patients social distancing, patient education, availabil-
ity of rapid testing, the continuation of antitubercular 
therapy, establishment of a robust triaging, specialized 
care unit, international scientific collaboration, and gov-
ernmental support would be crucial in controlling the 
cumulative impact of both these infections. (39-41) 
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Conclusion: 
Studies on the impact of COVID-19 in patients 
with TB are limited. Most cases reported have been 
from Italy. This co-infection has been reported in 
patients across all age groups. Co-infection rates are 
higher in males and migrants. Most reported patients 
with co-infection have been symptomatic. In these 
symptomatic patients with COVID 19 and TB, the 
clinical presentation, and the imaging findings tend to 
be similar to the patients without TB.  Elderly patients 
and patients with more than two comorbidities are 
reported to be at higher risk of mortality.
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